IL-17A, IL-17F and IL-23R Gene Polymorphisms in Polish Patients with Rheumatoid Arthritis
Among the complex network of inflammatory cells involved in the pathogenesis of rheumatoid arthritis (RA), Th17 cells have recently been identified as key cells in the promotion of autoimmune processes, and joint destruction. The IL-23/Th17 signalling pathway, consisting of IL-23/IL-23R, IL-17A and...
Gespeichert in:
Veröffentlicht in: | Archivum Immunologiae et Therapiae Experimentalis 2015-06, Vol.63 (3), p.215-221 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Among the complex network of inflammatory cells involved in the pathogenesis of rheumatoid arthritis (RA), Th17 cells have recently been identified as key cells in the promotion of autoimmune processes, and joint destruction. The IL-23/Th17 signalling pathway, consisting of IL-23/IL-23R, IL-17A and IL-17F encoding genes, represents a candidate way for RA development with possible involvement in disease susceptibility and effect on disease progression. The present study aimed to determine the association between the polymorphic variants of the
IL
-
17A
(rs2275913),
IL
-
17F
(rs763780) and
IL
-
23R
(rs11209026) genes and RA susceptibility, progression and response to therapy with TNF-α inhibitors. Eighty-nine patients and 125 healthy individuals were investigated. The
IL
-
17A
polymorphism was found to affect RA progression and response to anti-TNF treatment. Female patients carrying the
IL
-
17A
wild-type genotype more frequently presented with stage 4 (8/24 vs. 6/47;
p
= 0.058) and were characterized by more active disease (the highest DAS28 score >5.1) after 3 months of therapy with the TNF inhibitors (12/23 vs. 15/45;
p
= 0.040). The
IL
-
17F
polymorphism appeared to be associated with susceptibility to the disease. The presence of the
IL
-
17F
minor variant (OR 3.97;
p
|
---|---|
ISSN: | 0004-069X 1661-4917 |
DOI: | 10.1007/s00005-014-0319-5 |